Rituximab in the treatment of jo1 antibody-associated antisynthetase syndrome: Anti-Ro52 positivity as a marker for severity and treatment response

Journal of Rheumatology

Volumn 43, Issue 8, 2016, Pages 1566-1574

  Bauhammer, Jutta ^a   Blank, Norbert ^b   Max, Regina ^b   Lorenz, Hanns Martin ^a,b   Wagner, Ulrich ^c   Krause, Dietmar ^d   Fiehn, Christoph ^a  

^a ACURA Centre for Rheumatic Diseases   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Department of Thoracic and Vascular Surgery   (Germany)

^d RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Antisynthetase antibodies; Interstitial lung disease; Jo1 Ro52; Polymyositis

Indexed keywords

ANTIBODY; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLIXIMAB; JO 1 ANTIBODY; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; PREDNISOLONE; RITUXIMAB; RO52 ANTIBODY; TACROLIMUS; UNCLASSIFIED DRUG; AUTOANTIBODY; IMMUNOSUPPRESSIVE AGENT; RIBONUCLEOPROTEIN; SS-A ANTIGEN;

ADULT; ADVERSE OUTCOME; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTISYNTHETASE SYNDROME; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; DERMATOMYOSITIS; DISEASE DURATION; DISEASE MARKER; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG SAFETY; FEMALE; FOLLOW UP; FORCED VITAL CAPACITY; HIGH RISK PATIENT; HUMAN; HYPERTENSIVE CRISIS; INTERSTITIAL LUNG DISEASE; JO1 ANTISYNTHETASE SYNDROME; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PNEUMONIA; POLYMYOSITIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UROSEPSIS; IMMUNOLOGY; MIDDLE AGED; MYOSITIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; AUTOANTIBODIES; DERMATOMYOSITIS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MYOSITIS; RETROSPECTIVE STUDIES; RIBONUCLEOPROTEINS; RITUXIMAB; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84982845441     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.150844     Document Type: Article

References (38)

1. Mahler M, Miller FW, Fritzler MJ. Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. Autoimmun Rev 2014;13:367-71.
2. Maurer B. [Early symptoms of dermatomyositis and antisynthetase syndrome]. [Article in German] Z Rheumatol 2013;72:970-6.
3. Ghirardello A, Bassi N, Palma L, Borella E, Domeneghetti M, Punzi L, et al. Autoantibodies in polymyositis and dermatomyositis. Curr Rheumatol Rep 2013;15:335.
4. Marie I, Josse S, Hatron PY, Dominique S, Hachulla E, Janvresse A, et al. Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome. Arthritis Care Res 2013;65:800-8.
5. Tillie-Leblond I, Wislez M, Valeyre D, Crestani B, Rabbat A, Israel-Biet D, et al. Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. Thorax 2008;63:53-9.
6. Schulte-Pelkum J, Fritzler M, Mahler M. Latest update on the Ro/SS-A autoantibody system. Autoimmun Rev 2009;8:632-7.
7. Rutjes SA, Vree Egberts WT, Jongen P, Van Den Hoogen F, Pruijn GJ, Van Venrooij WJ. Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clin Exp Immunol 1997;109:32-40.
8. Brouwer R, Hengstman GJ, Vree Egberts W, Ehrfeld H, Bozic B, Ghirardello A, et al. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001;60:116-23.
9. Marie I, Hatron P Y, Dominique S, Cherin P, Mouthon L, Menard JF, et al. Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody. Semin Arthritis Rheum 2012;41:890-9.
10. La Corte R, Lo Mo Naco A, Locaputo A, Dolzani F, Trotta F. In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease. Autoimmunity 2006;39:249-53.
11. Váncsa A, Csípo I, Németh J, Dévényi K, Gergely L, Dankó K. Characteristics of interstitial lung disease in SS-A positive/Jo-1 positive inflammatory myopathy patients. Rheumatol Int 2009;29:989-94.
12. Lambotte O, Kotb R, Maigne G, Blanc FX, Goujard C, Delfraissy JF. Efficacy of rituximab in refractory polymyositis. J Rheumatol 2005;32:1369-70.
13. Brulhart L, Waldburger JM, Gabay C. Rituximab in the treatment of antisynthetase syndrome. Ann Rheum Dis 2006;65:974-5.
14. Sultan SM, Ng KP, Edwards JC, Isenberg DA, Cambridge G. Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy. Clin Exp Rheumatol 2008;26:887-93.
15. Sem M, Molberg Ø, Lund MB, Gran JT. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology 2009;48:968-71.
16. Vandenbroucke E, Grutters JC, Altenburg J, Boersma WG, ter Borg EJ, van den Bosch JM. Rituximab in life threatening antisynthetase syndrome. Rheumatol Int 2009;29:1499-502.
17. Zappa MC, Trequattrini T, Mattioli F, Rivitti R, Vigliarolo R, Marcoccia A, et al. Rituximab treatment in a case of antisynthetase syndrome with severe interstitial lung disease and acute respiratory failure. Multidiscip Respir Med 2011;6:183-8.
18. Limaye V, Hissaria P, Liew CL, Koszyka B. Efficacy of rituximab in refractory antisynthetase syndrome. Intern Med J 2012;42:e4-7.
19. Marie I, Dominique S, Janvresse A, Levesque H, Menard JF. Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome. Respir Med 2012;106:581-7.
20. Nalotto L, Iaccarino L, Zen M, Gatto M, Borella E, Domenighetti M, et al. Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature. Immunol Res 2013;56:362-70.
21. Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM, et al; RIM Study Group, Oddis CV. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol 2014;66:740-9.
22. Andersson H, Sem M, Lund MB, Aaløkken TM, Günther A, Walle-Hansen R, et al. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Rheumatology 2015;54:1420-8.
23. Doyle T, Osorio J, DeMagaldi EN, Madan R, Cabral F, Rosas I, et al. Assessment of the effect of rituximab in the treatment of interstitial lung disease associated with the antisynthetase syndrome [abstract]. Arthritis Rheumatol 2014;66 Suppl 11:S557.
24. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-7.
25. Oddis CV, Rider LG, Reed AM, Ruperto N, Brunner HI, Koneru B, et al; International Myositis Assessment and Clinical Studies Group. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 2005;52:2607-15.
26. Rider L, Giannini EH, Brunner HI, Ruperto N, James-Newton L, Reed AM, et al; International Myositis Assessment and Clinical Studies Group. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 2004;50:2281-90.
27. Katzap E, Barilla-LaBarca ML, Marder G. Antisynthetase syndrome. Curr Rheumatol Rep 2011;13:175-81.
28. Cavagna L, Caporali R, Abdì-Alì L, Dore R, Meloni F, Montecucco C. Cyclosporine in anti-Jo1-positive patients with corticosteroid-refractory interstitial lung disease. J Rheumatol 2013;40:484-92.
29. Labirua-Iturburu A, Selva-O'Callaghan A, Martínez-Gómez X, Trallero-Araguás E, Labrador-Horrillo M, Vilardell-Tarrés M. Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease. Clin Exp Rheumatol 2013;31:436-9.
30. Hosono Y, Nakashima R, Imura Y, Yukawa N, Yoshifuji H, Nojima T, et al. The early use of cyclosporine is beneficial for long-term prognosis in patients of polymyositis/dermatomyositis-associated interstitial lung disease with anti-synthetase antibodies [abstract]. Arthritis Rheumatol 2014;66 Suppl 11:S552.
31. Gómez-Martín D, Díaz-Zamudio M, Alcocer-Varela J. Ubiquitination system and autoimmunity: the bridge towards the modulation of the immune response. Autoimmun Rev 2008; 7:284-90.
32. Espinosa A, Zhou W, Ek M, Hedlund M, Brauner S, Popovic K, et al. The Sjögren's syndrome-associated autoantigen Ro52 is an E3 ligase that regulates proliferation and cell death. J Immunol 2006;176:6277-85.
33. Rhodes DA, Ihrke G, Reinicke AT, Malcherek G, Towey M, Isenberg DA, et al. The 52 000 MW Ro/SS-A autoantigen in Sjögren's syndrome/systemic lupus erythematosus (Ro52) is an interferon-γ inducible tripartite motif protein associated with membrane proximal structures. Immunology 2002;106:246-56.
34. Higgs R, Lazzari E, Wynne C, Ni Gabhann J, Espinosa A, Wahren-Herlenius M, et al. Self protection from anti-viral responses-Ro52 promotes degradation of the transcription factor IRF7 downstream of the viral Toll-Like receptors. PLoS One 2010;5:e11776.
35. Higgs R, Ni Gabhann J, Ben Larbi N, Breen EP, Fitzgerald KA, Jefferies CA. The E3 ubiquitin ligase Ro52 negatively regulates IFN-beta production post-pathogen recognition by polyubiquitin-mediated degradation of IRF3. J Immunol 2008;181:1780-6.
36. Kong HJ, Anderson DE, Lee CH, Jang MK, Tamura T, Tailor P, et al. Cutting edge: autoantigen Ro52 is an interferon inducible E3 ligase that ubiquitinates IRF-8 and enhances cytokine expression in macrophages. J Immunol 2007;179:26-30.
37. Espinosa A, Dardalhon V, Brauner S, Ambrosi A, Higgs R, Quintana FJ, et al. Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23-Th17 pathway. J Exp Med 2009;206:1661-71.
38. Espinosa A, Hennig J, Ambrosi A, Anandapadmanaban M, Abelius MS, Sheng Y, et al. Anti-Ro52 autoantibodies from patients with Sjögren's syndrome inhibit the Ro52 E3 ligase activity by blocking the E3/E2 interface. J Biol Chem 2011;286:36478-91.